Collegium Pharmaceutical, Inc. COLL Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $193.52M+8.9% | $205.45M+12.9% | $209.36M+31.4% | $188M+29.4% | $177.76M+22.7% | ||
| $76.27M-5.2% | $77.07M-7.9% | $80.19M+28.3% | $79.62M+46.2% | $80.43M+50.4% | ||
| $117.25M+20.5% | $128.38M+30.6% | $129.17M+33.4% | $108.38M+19.4% | $97.32M+6.4% | ||
| 60.6%+5.8pp | 62.5%+8.5pp | 61.7%+0.9pp | 57.7%-4.9pp | 54.8%-8.4pp | ||
| $86.35M+13.0% | $67.64M+7.2% | $67.1M+8.3% | $73.64M+69.9% | $76.42M+82.0% | ||
| $86.35M+14.2% | $67.62M+12.4% | $67.08M+8.3% | $73.28M+69.1% | $75.64M+80.2% | ||
| $86.35M+14.2% | $67.62M+12.4% | $67.08M+8.3% | $73.28M+69.1% | $75.64M+80.2% | ||
| $30.9M+42.5% | $60.76M+59.4% | $62.09M+78.2% | $35.11M-26.0% | $21.69M-56.2% | ||
| 16%+3.8pp | 29.6%+8.6pp | 29.7%+7.8pp | 18.7%-14.0pp | 12.2%-21.9pp | ||
| $15.86M-23.7% | $19.29M-14.8% | $21.77M+18.3% | $20.46M+31.3% | $20.79M+19.9% | ||
| $3.71M+66.6% | $3.57M+96.7% | $3.12M-5.0% | $2.38M-45.8% | $2.23M-50.4% | ||
| $18.74M+500% | $29.04M+68.1% | $43.44M+179% | $17.03M-41.5% | $3.12M-91.5% | ||
| $4.24M+502% | $12.07M+155% | $11.93M+91.0% | $5.04M-46.9% | $705K-92.1% | ||
| $14.5M+500% | $16.96M+35.3% | $31.51M+238% | $11.98M-38.9% | $2.42M-91.3% | ||
| 7.5%+6.1pp | 8.3%+1.4pp | 15%+9.2pp | 6.4%-7.1pp | 1.4%-17.8pp | ||
| $0.40+471% | $0.46+27.8% | $0.84+211% | $0.34-34.6% | $0.07-90.1% | ||
| $0.45+463% | $0.54+38.5% | $1.00+245% | $0.38-36.7% | $0.08-90.7% | ||
| 40.1M+22.0% | 40.1M-0.1% | 39.4M-1.8% | 39.1M-3.2% | 32.8M-20.7% | ||
| 32.1M+0.9% | 31.7M-1.3% | 31.6M-2.1% | 31.8M-1.9% | 31.8M-1.6% | ||
| $55.47M0.0% | —— | —— | —— | $55.47M+34.2% | ||
| $0+100% | -$19K+99.3% | -$19K— | -$358K— | -$786K— | ||
| $3.71M+66.6% | $3.57M+96.7% | $3.12M-5.0% | $2.38M-45.8% | $2.23M-50.4% | ||
| $193.52M+8.9% | $205.45M+12.9% | $209.36M+31.4% | $188M+29.4% | $177.76M+22.7% | ||
| $30.9M+42.5% | $60.76M+59.4% | $62.09M+78.2% | $35.11M-26.0% | $21.69M-56.2% | ||
| $86.83M+11.0% | $61.68M-34.8% | $63.12M-17.6% | $36.24M-56.3% | $78.25M-7.8% | ||
| $86.83M+11.0% | $61.68M-34.8% | $63.12M-17.6% | $36.24M-56.3% | $78.25M-7.8% | ||
| 44.9%+0.8pp | 30%-22.0pp | 30.1%-17.9pp | 19.3%-37.8pp | 44%-14.6pp | ||
| $30.9M+42.5% | $60.76M+59.4% | $62.09M+78.2% | $35.11M-26.0% | $21.69M-56.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s revenue?
- Collegium Pharmaceutical, Inc. (COLL) generated $796.3M in revenue over the trailing twelve months, up 19.9% year over year.
- Is Collegium Pharmaceutical, Inc. profitable?
- Collegium Pharmaceutical, Inc. reported $74.9M in net income over the trailing twelve months, a 9.4% net margin.
- What are Collegium Pharmaceutical, Inc.'s profit margins?
- Gross margin is 60.7% and operating margin is 23.7%, with a 9.4% net margin.
- What is Collegium Pharmaceutical, Inc.'s earnings per share?
- Collegium Pharmaceutical, Inc.'s diluted EPS over the trailing twelve months is $2.04.
- Where does Collegium Pharmaceutical, Inc.'s income statement data come from?
- Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
